Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Oncology
  • Oncology News
  • Study focuses on...

Study focuses on resistance to androgen receptor-targeted therapy in advanced prostate cancer

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2025-04-09T20:00:40+05:30  |  Updated On 9 April 2025 8:00 PM IST
AstraZeneca discontinues Phase 3 trial of Truqap in metastatic castration-resistant prostate cancer
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, placing it second behind lung cancer as the leading cause of cancer death among American males.

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor, they regulate the growth of prostate cancer cells, making the androgen receptor a primary target for treatments using androgen receptor signaling inhibitors. However, prostate cancer eventually becomes resistant to the inhibitors, which leads to a form of disease known as castrate-resistant prostate cancer.

Attempts to overcome this resistance have spurred the development of more potent antiandrogens, such as enzalutamide. In many cases, however, these advanced therapies ultimately fail, highlighting the need for new approaches to restore sensitivity in castrate-resistant prostate cancer and improve treatment outcomes.

In an effort to find new treatments for castrate-resistant prostate cancer, a Texas Tech University Health Sciences Center (TTUHSC) research team led by Srinivas Nandana, Ph.D., and Manisha Tripathi, Ph.D., from the Department of Cell Biology and Biochemistry at the TTUHSC School of Medicine recently completed a study that focused on uncovering the molecular and signaling mechanisms that drive the progression of advanced prostate cancer. Their study (“A TBX2-Driven Signaling Switch from Androgen Receptor to Glucocorticoid Receptor Confers Therapeutic Resistance in Prostate Cancer”), which was published in December 2024 by Oncogene, placed particular emphasis on overcoming resistance to androgen receptor signaling inhibitors.

The research team included members from the Nandana and Tripathi labs. Sayanika Dutta, a graduate student in the Nandana lab, led the study. Other key contributors from TTUHSC included Hamed Khedmatgozar, a graduate student from the Tripathi lab; former research associates Daniel Latour and Jonathan Welsh; and Girijesh Kumar Patel, Ph.D., a former postdoctoral fellow in both labs and now a faculty member in the Department of Biotechnology at Motilal Nehru National Institute of Technology in Allahabad, India. The team also collaborated with Mainak Mustafi, Ph.D., and Antonina Mitrofanova, Ph.D., from the Department of Health Informatics at Rutgers School of Health Professions in Newark, New Jersey.

The study was primarily funded by grants from the U.S. Department of Defense, the Cancer Prevention Research Institute of Texas-Texas Regional Excellence in Cancer, the Ted Nash Long Life Foundation and The CH Foundation.

“In our lab, we study a protein called TBX2, a transcription factor (a protein that helps to convert DNA into RNA) that regulates the expression of multiple genes,” Nandana said. “Previous studies from our team have shown that TBX2 is over-expressed in castrate-resistant prostate cancer, and the goal of this project was to investigate how TBX2 drives castrate-resistant prostate cancer development, particularly its role in conferring resistance to enzalutamide.”

Based upon their previous research, the Nandana-Tripathi team knew the TBX2 protein is elevated in advanced prostate cancer, especially in castrate-resistant prostate cancer. However, Nandana said the study revealed three unexpected and significant findings.

The first finding showed that TBX2 drives therapy resistance in castrate-resistant prostate cancer by acting as a switch, shifting the signaling pathway from the androgen receptor to the glucocorticoid receptor. Nandana said it achieves this by rerouting cellular signaling from the androgen receptor to the glucocorticoid receptor, allowing cancer cells to continue growing despite treatment. Second, the team identified a strategy to target this TBX2-driven switch in prostate cancer by disrupting the protein complex with which TBX2 interacts. Third, the study consistently showed pairwise correlations between the protein activities of TBX2, androgen receptors and glucocorticoid receptors in castrate-resistant prostate cancer patients and in patients with early-stage prostate cancer who initially respond to androgen-receptor targeted therapies.

“Resistance to androgen-receptor targeted treatments is a major challenge in treating advanced prostate cancer,” Nandana said. “Our study suggests that by looking at the relationships between the TBX2, the androgen receptor and the glucocorticoid receptor proteins in early stages of the disease, we might be able to predict which patients are at higher risk of developing advanced prostate cancer, particularly castrate-resistant prostate cancer that no longer responds to treatments like enzalutamide. Identifying these patients early could open the door to therapies that target the androgen receptor-to-glucocorticoid receptor switch, including those that disrupt TBX2 function, offering a promising new treatment approach.”

Nandana said this discovery is significant because scientists have long been searching for ways to restore sensitivity to androgen receptor signaling inhibitors in prostate cancer. The team’s findings suggest a promising approach that could block the harmful switch without the severe side effects typically associated with directly targeting transcription factors like glucocorticoid receptors, offering a potentially safer and more effective treatment strategy.

“Our next steps involve creating new models of castrate-resistant prostate cancer to further investigate other molecular factors that drive the switch from the androgen receptor to the glucocorticoid receptor in castrate-resistant prostate cancer,” Nandana said. “Additionally, we aim to identify novel drugs that could target this mechanism and offer potential new treatments for castrate-resistant prostate cancer.”

Reference:

Dutta, S., Khedmatgozar, H., Patel, G.K. et al. A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer. Oncogene 44, 877–892 (2025). https://doi.org/10.1038/s41388-024-03252-5

American Cancer SocietyOncogeneprostate cancercancerenzalutamide
Source : Oncogene
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

View All

Journal Club Today

Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

View All

Health News Today

Health Bulletin 24/May/2025

Health Bulletin 24/May/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok